Form 8-K - Current report:
SEC Accession No. 0001628280-24-048527
Filing Date
2024-11-19
Accepted
2024-11-19 17:15:04
Documents
16
Period of Report
2024-11-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K syre-20241118.htm   iXBRL 8-K 35330
2 EX-1.1 exhibit11-8xkfinancialclos.htm EX-1.1 334289
3 EX-5.1 exhibit51-8xkfinancialclos.htm EX-5.1 8232
7 exhibit511a.jpg GRAPHIC 54852
  Complete submission text file 0001628280-24-048527.txt   653738

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT syre-20241118.xsd EX-101.SCH 1777
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT syre-20241118_lab.xml EX-101.LAB 23727
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT syre-20241118_pre.xml EX-101.PRE 13584
18 EXTRACTED XBRL INSTANCE DOCUMENT syre-20241118_htm.xml XML 2927
Mailing Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 23, SUITE 105 WALTHAM MA 02453 6176515940
Spyre Therapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 241477279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)